KADCYLA efficacy: 50% reduction in the risk of recurrence vs Herceptin® (trastuzumab)*1

KATHERINE trial overview1,2

  • Randomized, open-label trial of 1486 patients with HER2+ EBC who had residual invasive disease in the breast and/or axillary lymph nodes following neoadjuvant treatment with taxane + Herceptin-based therapy
  • Designed to assess efficacy and safety of KADCYLA vs Herceptin in the adjuvant setting
  • Administered every 3 weeks for a total of 14 cycles or until recurrence, withdrawal of consent, or unmanageable toxicity

iDFS in the overall study population after a median follow-up of 40 months1

*Recurrence is defined as an invasive-disease event or death.

3-year iDFS rates were 88.3% for KADCYLA vs 77.0% for Herceptin1

Overall survival (OS) was a secondary endpoint and was not mature at the time of iDFS analysis (98 OS events [6.6%] occurred in 1486 patients).

KADCYLA showed consistent iDFS results across subgroups†1

Exploratory analysis of select pre-specified subgroups2

Including stratification factors, key baseline demographics and disease characteristics, and prior treatments.
Five patients with a ypT1 tumor stage had ypT1 disease without further subspecification.2
§18.3% (n=272) of patients were treated with PERJETA® (pertuzumab) + Herceptin-based therapy in the neoadjuvant setting, and had an iDFS hazard ratio of 0.50 (95% CI 0.25-1.00). The other 18 patients received Herceptin and either neratinib, dacomitinib, afatinib, or lapatinib.2

How KADCYLA was studied

Review the adverse reactions

Dosing for KADCYLA in EBC